Alembic Pharmaceuticals · NSE: APLLTD · BSE: 533573

Q3 FY25 results · Oct–Dec 2024

Alembic Pharmaceuticals reported revenue from operations of ₹1,692.74 crore (up 3.8% from Q3 FY24) and net profit of ₹137.69 crore (down 23.7% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY25	Q3 FY24	YoY	Q2 FY25	QoQ
Revenue from operations	1,692.74	1,630.57	+3.8%	1,647.98	+2.7%
Other income	9.50	2.89	+228.5%	16.75	−43.2%
Total income	1,702.25	1,633.46	+4.2%	1,664.72	+2.3%
Profit before share of associates & JVs and tax	177.43	184.63	−3.9%	179.56	−1.2%
Share of profit/(loss) of associates & JVs	0.35	(0.05)		0.86
Net profit for the period	137.69	180.46	−23.7%	153.15	−10.1%
Attributable to shareholders of the company	138.41	180.46	−23.3%	153.41	−9.8%
EPS, basic (₹)	7.00	9.18	−23.7%	7.79	−10.1%
Net margin (%)	8.1	11.1		9.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY25	Q3 FY24	YoY	Q2 FY25	QoQ
Revenue from operations	1,406.09	1,588.39	−11.5%	1,580.35	−11.0%
Other income	15.46	3.30	+368.5%	16.06	−3.7%
Total income	1,421.55	1,591.69	−10.7%	1,596.41	−11.0%
Profit before tax	103.81	256.70	−59.6%	200.02	−48.1%
Net profit for the period	85.81	233.24	−63.2%	165.78	−48.2%
EPS, basic (₹)	4.37	11.87	−63.2%	8.43	−48.2%
Net margin (%)	6.1	14.7		10.5

Consolidated

Filed with BSE: 03 Feb 2025, 16:52 IST
Board meeting: 03 Feb 2025
Period: 01 Oct 2024 to 31 Dec 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 03 Feb 2025, 16:52 IST
Board meeting: 03 Feb 2025
Period: 01 Oct 2024 to 31 Dec 2024
Review status: Unaudited
Source: XBRL filing on BSE